Oxilorphan
Oxilorphan
|
| Systematic (IUPAC) name |
| (-)-17-(cyclopropylmethyl)-morphinan-3,14-diol |
| Clinical data |
| Pregnancy cat. |
? |
| Legal status |
? |
| Identifiers |
| CAS number |
42281-59-4 |
| ATC code |
None |
| PubChem |
CID 5361090 |
| ChemSpider |
16736680 Y |
| UNII |
9Y9J2J74TO Y |
| KEGG |
D05299 Y |
| Chemical data |
| Formula |
C20H27NO2 |
| Mol. mass |
313.44 g/mol |
| SMILES |
eMolecules & PubChem |
-
InChI=1S/C20H27NO2/c22-16-6-5-15-11-18-20(23)8-2-1-7-19(20,17(15)12-16)9-10-21(18)13-14-3-4-14/h5-6,12,14,18,22-23H,1-4,7-11,13H2/t18-,19+,20-/m1/s1 Y
Key:STBZIDOIKQNFCQ-HSALFYBXSA-N Y
|
Y(what is this?) (verify)
|
Oxilorphan is an opioid antagonist from the morphinan family of drugs.
Oxilorphan is a non-selective opioid which is a μ antagonist but a κ partial agonist. It has similar effects to naloxone, and around the same potency as an antagonist.[1]
Oxilorphan has some weak partial agonist effects[2] and can produce hallucinogenic effects at high doses, suggesting some kappa opioid agonist action.[3] It was trialled for the treatment of opiate addiction, but was not developed commercially.[4]
See also
References
- ^ Pircio AW, Gylys JA. Oxilorphan (l-N-cyclopropylmethyl-3,14-dihydroxymorphinan): a new synthetic narcotic antagonist. Journal of Pharmacology and Experimental Therapeutics. 1975 Apr;193(1):23-34.
- ^ Sellers EM, Thakur R. Partial agonist properties and toxicity of oral oxilorphan. Journal of Clinical Pharmacology. 1976 Apr;16(4):183-7.
- ^ Leander JD. Evidence that nalorphine, butorphanol and oxilorphan are partial agonists at a kappa-opioid receptor. European Journal of Pharmacology. 1983 Jan 21;86(3-4):467-70.
- ^ Tennant FS Jr, Tate JA, Ruckel E. Clinical trial in post-addicts with oxilorphan (levo-BC-2605): a new narcotic antagonist. Drug and Alcohol Dependence. 1976 Jun;1(5):329-37.